Bachem Holding AG Class B (BCHMF)
OTHER OTC:BCHMF
BCHMF Stock Chart & Stats
$89.59
--
Market closed
$89.59
--
Day’s Range― - ―
52-Week Range$58.30 - $108.92
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$6.42B
Enterprise Value$5.79B
Total Cash (Recent Filing)$30.99M
Total Debt (Recent Filing)$57.39M
Price to Earnings (P/E)34.5
Beta1.29
Next Earnings
Jul 30, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)1.99
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue8.32
Enterprise Value/Gross Profit28.96
Enterprise Value/Ebitda32.17
Forecast
1Y Price Target
$106.60Price Target Upside18.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.98
Revenue Forecast (FY)$1.19B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a growing equity base provide durable financial resilience, enabling sustained investment in capacity and R&D, buffering revenue volatility and reducing refinancing risk. This supports long-term stability and strategic optionality even during downturns.
Steady Revenue Expansion And Solid MarginsConsistent top-line growth combined with healthy net margins indicates persistent demand for peptide APIs and services, supporting repeatable profitability. This trend underpins reinvestment ability and operational scalability across clinical to commercial production stages.
Recurring Commercial Supply ModelA business model built on long-term supply contracts and development work that converts into commercial manufacturing creates durable revenue visibility and customer stickiness. Successful project transitions can generate multi-year commercial revenue streams.
Bears Say
Persistent Negative Free Cash FlowOngoing negative free cash flow, driven by elevated capex or working-capital absorption, reduces internal funding for expansion and dividends and increases reliance on external financing. Over months, this can constrain strategic flexibility if not reversed.
Recent Step-up In DebtWhile leverage remains low, the 2025 increase in debt marks a shift from near-zero prior levels. If cash conversion remains weak, even modest debt growth can raise financing costs and reduce balance sheet optionality, warranting monitoring of debt servicing ability.
Gradual Margin CompressionA gradual decline in margins versus earlier peak years suggests structural pressures—pricing, mix shift to lower-margin clinical work, or rising input costs. Persistent compression would erode return on equity and limit cash available for reinvestment over the medium term.
Bachem Holding AG News
BCHMF FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was $58.30 and its highest was $108.92 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is $6.42B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 30, 2026 which is in 49 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported $1.652 earnings per share for the quarter, beating the consensus estimate of $1.155 by $0.497.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of $0.575 which represents an annual dividend yield of 1.45%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.48.
How many shares outstanding does Bachem Holding AG Class B have?
Currently, no data Available
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of $1.652 in its last earnings report, beating expectations of $1.155. Following the earnings report the stock price went up 8.803%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in BCHMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
BCHMF Stock 12 Month Forecast
Average Price Target
$106.60
▲(18.98% Upside)
Ownership Overview
―
Insiders
1.24% Mutual Funds
― Other Institutional Investors
96.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---